Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma (SSAT042)
The study's chief objective is to observe the evolution of cellular (in terms of expression of transmembrane transporters and their transcriptional regulators) and viral resistance (in terms of development of mutations in the HIV genome that may confer resistance to future treatment for HIV) in HIV-infected patients with lymphoma.
|Study Design:||Observational Model: Case Control|
|Official Title:||Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma|
- Development of multi-drug resistance (in terms of expression of transmembrane transporters and their transcriptional regulators) in HIV-infected patients with lymphoma. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Development of mutations in the HIV genome that may confer resistance to future treatment for HIV. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
|Study Start Date:||May 2011|
|Estimated Study Completion Date:||May 2014|
|Estimated Primary Completion Date:||May 2014 (Final data collection date for primary outcome measure)|
HIV patients without lymphoma
HIV-infected subjects on cART without a diagnosis of lymphoma
HIV patients with lymphoma
HIV seropositive individuals with lymphoma
The study team will take two or three tubes of blood on three occasions during the course of chemotherapy. The total amount of blood required for this research project is 64mL (approximately 4 tablespoons).
This will allow better understanding of the changes that take place in the blood and the HIV virus itself. It is hoped that this will provide new insights that may aid the understanding and treatment of HIV patients with lymphoma.
|Contact: Marta Boffito, Dr||020 3315 email@example.com|
|St Stephen's Centre||Recruiting|
|London, United Kingdom, SW10 9NH|
|Contact: Marta Boffito, Dr firstname.lastname@example.org|
|Principal Investigator: Marta Boffito, Dr|
|Principal Investigator:||Marta Boffito, Dr||St Stephen's AIDS Trust|